TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL
TP53 突变与 CD19 阴性复发以及成人急性淋巴细胞白血病 (ALL) 患者接受 blinatumomab 治疗后预后不良相关。
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024014986
Aldoss, Ibrahim; Li, Shanpeng; Zhang, Jianying; Clark, Mary C; Agrawal, Vaibhav; Pourhassan, Hoda; Koller, Paul; Aribi, Ahmed; Ali, Haris; Blackmon, Amanda; Otoukesh, Salman; Sandhu, Karamjeet; Ball, Brian; Arslan, Shukaib; Artz, Andrew; Amanam, Idoroenyi; Al Malki, Monzr M; Salhotra, Amandeep; Kovacsovics, Tibor; Murphy, Lindsey; Afkhami, Michelle; Ngo, Dat; Tinajero, Jose; Gu, Zhaohui; Becker, Pamela S; Nakamura, Ryotaro; Stein, Anthony; Marcucci, Guido; Forman, Stephen J; Pullarkat, Vinod